The SURPASS trials: Summarizing efficacy data on tirzepatide
What you need to know
The novel type 2 diabetes medication tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Its efficacy is being tested in the phase 3 SURPASS clinical trial program, with results of the cardiovascular outcomes study and a trial of tirzepatide in people with obesity but without diabetes expected in 2024. Explore this page for trial results and expert commentary, updated as new results are reported.
SURPASS-1 trial results & series summary